U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939087) titled 'A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy Volunteers' on Nov. 10.
Brief Summary: The purpose of this study is to evaluate the pharmacokinetics and safety compared to HIP2604 and RLD2606 in healthy volunteers.
Study Start Date: Jan. 12, 2027
Study Type: INTERVENTIONAL
Condition:
Healty Volunteers
Intervention:
DRUG: RLD2606
Take 1 tablet once per period
DRUG: HIP2604 1
Take 1 tablet once per period
DRUG: HIP2604 2
Take 1 tablet once per period
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hanmi Pharmaceutical Company Limited
Published by HT Digital Content Services with...